Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned an average recommendation of “Buy” from the four brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating on the company.

A number of brokerages have recently weighed in on BAYRY. Wall Street Zen upgraded Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Hsbc Global Res raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 11th. Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Wednesday, June 11th. Zacks Research cut shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 1st. Finally, The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 5th.

Bayer Aktiengesellschaft Trading Down 0.4%

Bayer Aktiengesellschaft stock opened at $8.26 on Wednesday. The stock has a 50-day simple moving average of $8.01 and a 200 day simple moving average of $7.12. The stock has a market capitalization of $32.46 billion, a P/E ratio of -8.52, a PEG ratio of 3.78 and a beta of 0.93. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. Bayer Aktiengesellschaft has a 52 week low of $4.79 and a 52 week high of $8.65.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.10. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.44%. The firm had revenue of $12.42 billion during the quarter, compared to analysts’ expectations of $10.79 billion. Analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.